Last 12 months
Inside the activity.
0 purchase rows · 24 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 9 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2017 Filed Oct 16, 2017 21:15 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
Exercise / conversionCommon Stock | 1,426,590 | $1.38 | $1,968,694.20 |
DisclosureSEC source: 0001638599-17-001019 · doc4_5024.xml · nonDerivative · entry 3 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 23,763,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On October 13, 2017, Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 14159 and 667, the "Funds") exercised a warrant to purchase 1,426,590 shares of the common stock of the Issuer for $1.38 per share ("2018 Warrants"). Life Sciences paid the exercise price on a cashless basis, resulting in the Issuer withholding of 55,457 of the 2018 Warrant shares to pay the exercise price and issuing to Life Sciences the remaining 1,371,133 shares of common stock of the Issuer. The Issuer also paid $29.30 to Life Sciences in fractional shares. The Issuer's Board of Directors approved the exercise of the 2018 Warrants by Life Sciences on the cashless basis described in this footnote in advance of such exercise. F4 · ownership.nature: As a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of common stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. F5 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · derivative · entry 11 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2018-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 50% of the shares subject to the Stock Option vested and became exercisable on October 20, 2010. The remaining shares vested and became exercisable thereafter in 24 equal monthly installments. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · derivative · entry 10 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · derivative · entry 9 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,500 Underlying: Common Stock · 1,000 shares Expires 2022-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 23, 2013. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC |
Baity GlennEVP AND GC
|
SaleCommon Stock | 37,500 | $40.91 | $1,534,042.50 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 6 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,656 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017. F2 · shares: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.605 to $41.065 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 20,000 | $2.00 | $40,000.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 5 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 7,500 | $1.62 | $12,150.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 4 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 22:20 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 1,000 | $2.18 | $2,180.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 22:20 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · derivative · entry 8 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,500 Underlying: Common Stock · 4,500 shares Expires 2022-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 23, 2013. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 22:20 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · derivative · entry 7 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 6,500 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 22:20 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 4,500 | $2.18 | $9,810.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 22:20 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 6,500 | $1.62 | $10,530.00 |
DisclosureSEC source: 0001415889-17-001636 · form4-10062017_031038.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 22:16 UTC |
YOUNG TODD S.EVP AND CFO
|
GrantStock Option (right to buy) · Derivative | 56,250 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001415889-17-001473 · form4-09082017_030900.xml · derivative · entry 1 YOUNG TODD S. · CIK 0001682584 · EVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2027-09-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 22:15 UTC |
Baity GlennEVP AND GC
|
GrantStock Option (right to buy) · Derivative | 46,875 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001415889-17-001472 · form4-09082017_030909.xml · derivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 46,875 shares Expires 2027-09-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 22:14 UTC |
YANG MICHAEL J.EVP AND CCO
|
GrantStock Option (right to buy) · Derivative | 93,750 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001415889-17-001471 · form4-09082017_030923.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP AND CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 93,750 shares Expires 2027-09-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 22:13 UTC | GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001415889-17-001470 · form4-09082017_030927.xml · derivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2027-09-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
|
| September 07, 2017 Filed Sep 8, 2017 22:08 UTC |
DAVIS STEPHENDirector · PRESIDENT AND CEO
|
GrantStock Option (right to buy) · Derivative | 243,750 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001415889-17-001469 · form4-09082017_030906.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,750 Underlying: Common Stock · 243,750 shares Expires 2027-09-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 21:15 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 16,507 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001447 · form4-09012017_020900.xml · derivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 16,507 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 21:15 UTC |
Baity GlennEVP AND GC
|
SaleCommon Stock | 26,507 | $34.87 | $924,314.99 |
DisclosureSEC source: 0001415889-17-001447 · form4-09012017_020900.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,656 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $34.88 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| August 30, 2017 Filed Sep 1, 2017 21:15 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 16,507 | $1.62 | $26,741.34 |
DisclosureSEC source: 0001415889-17-001447 · form4-09012017_020900.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 21:38 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 13,400 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001378 · form4-08112017_020820.xml · derivative · entry 5 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,507 Underlying: Common Stock · 13,400 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 21:38 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 922 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001415889-17-001378 · form4-08112017_020820.xml · derivative · entry 4 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 922 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 21:38 UTC |
Baity GlennEVP AND GC
|
SaleCommon Stock | 14,322 | $34.88 | $499,534.17 |
DisclosureSEC source: 0001415889-17-001378 · form4-08112017_020820.xml · nonDerivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,656 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $34.91 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 21:38 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 13,400 | $1.62 | $21,708.00 |
DisclosureSEC source: 0001415889-17-001378 · form4-08112017_020820.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 21:38 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 922 | $1.55 | $1,429.10 |
DisclosureSEC source: 0001415889-17-001378 · form4-08112017_020820.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2017 Filed Aug 8, 2017 22:29 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001348 · form4-08082017_030851.xml · derivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,907 Underlying: Common Stock · 6,500 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| August 04, 2017 Filed Aug 8, 2017 22:29 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 6,500 | $1.62 | $10,530.00 |
DisclosureSEC source: 0001415889-17-001348 · form4-08082017_030851.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 21:25 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 28,097 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001265 · form4-07212017_020745.xml · derivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,097 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 21:25 UTC |
Baity GlennEVP AND GC
|
SaleCommon Stock | 38,097 | $30.00 | $1,142,910.00 |
DisclosureSEC source: 0001415889-17-001265 · form4-07212017_020745.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,156 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 21:25 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 28,097 | $1.62 | $45,517.14 |
DisclosureSEC source: 0001415889-17-001265 · form4-07212017_020745.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 21:24 UTC |
Daly James MDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.85 | $0.00 |
DisclosureSEC source: 0001415889-17-001229 · form4-07192017_020709.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-07-16 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable at the end of each 3-month period following the date of ACADIA's 2017 Annual Meeting of Stockholders, or June 13, 2017. Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 21:25 UTC |
SOLAND DANIEL BDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.85 | $0.00 |
DisclosureSEC source: 0001415889-17-001230 · form4-07192017_020738.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-07-16 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable at the end of each 3-month period following the date of ACADIA's 2017 Annual Meeting of Stockholders, or June 13, 2017. Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 21:21 UTC |
HARRIGAN EDMUNDDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.85 | $0.00 |
DisclosureSEC source: 0001415889-17-001228 · form4-07192017_020747.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-07-16 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable at the end of each 3-month period following the date of ACADIA's 2017 Annual Meeting of Stockholders, or June 13, 2017. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 21:35 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,903 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-001046 · form4-06262017_020620.xml · derivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,097 Underlying: Common Stock · 1,903 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 21:35 UTC |
Baity GlennEVP AND GC
|
SaleCommon Stock | 1,903 | $30.00 | $57,090.76 |
DisclosureSEC source: 0001415889-17-001046 · form4-06262017_020620.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,156 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.01 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 21:35 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 1,903 | $1.62 | $3,082.86 |
DisclosureSEC source: 0001415889-17-001046 · form4-06262017_020620.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 20:06 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
667, L.P.Director · 10% owner
14159, L.P.Director · 10% owner
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $27.25 | $0.00 |
DisclosureSEC source: 0001638599-17-000592 · doc4_4788.xml · derivative · entry 1 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: 15,000 non-qualified stock options ("Stock Options") convertible solely into common shares of ACADIA Pharmaceuticals Inc. (the "Issuer") were granted to Julian C. Baker, a principal of Baker Bros. Advisors LP (the "Adviser") and 15,000 Stock Options were granted to Dr. Stephen R. Biggar, an employee of the Adviser in their capacity as directors of the Issuer. The Stock Options with a strike price of $27.25 vest in 4 equal quarterly installments beginning on June 13, 2017 and expire on June 12, 2027. Julian C. Baker and Dr. Biggar serve on the Board of Directors of the Issuer (the "Board") as representatives of Baker Brothers Life Sciences, L.P. ("Life Sciences"), 667, L.P. ("667") and 14159, L.P. ("14159", and together with 667 and Life Sciences, the "Funds"). F1 · ownership.nature: 15,000 non-qualified stock options ("Stock Options") convertible solely into common shares of ACADIA Pharmaceuticals Inc. (the "Issuer") were granted to Julian C. Baker, a principal of Baker Bros. Advisors LP (the "Adviser") and 15,000 Stock Options were granted to Dr. Stephen R. Biggar, an employee of the Adviser in their capacity as directors of the Issuer. The Stock Options with a strike price of $27.25 vest in 4 equal quarterly installments beginning on June 13, 2017 and expire on June 12, 2027. Julian C. Baker and Dr. Biggar serve on the Board of Directors of the Issuer (the "Board") as representatives of Baker Brothers Life Sciences, L.P. ("Life Sciences"), 667, L.P. ("667") and 14159, L.P. ("14159", and together with 667 and Life Sciences, the "Funds"). F2 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Biggar do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options (i.e. no direct pecuniary interest). F3 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. The Adviser has investment and dispositive power over the Stock Options and any shares received as a result of the exercise of options. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 22:16 UTC |
SOLAND DANIEL BDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.25 | $0.00 |
DisclosureSEC source: 0001415889-17-000993 · form4-06142017_030610.xml · derivative · entry 1 SOLAND DANIEL B · CIK 0001318485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 22:14 UTC |
HARRIGAN EDMUNDDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.25 | $0.00 |
DisclosureSEC source: 0001415889-17-000990 · form4-06142017_030611.xml · derivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 22:15 UTC |
Brege LauraDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.25 | $0.00 |
DisclosureSEC source: 0001415889-17-000991 · form4-06142017_030650.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 22:15 UTC |
Daly James MDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.25 | $0.00 |
DisclosureSEC source: 0001415889-17-000992 · form4-06142017_030634.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:42 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionStock Option (right to buy) · Derivative | 14,093 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-17-000785 · form4-05172017_020549.xml · derivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 14,093 shares Expires 2021-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:42 UTC |
Baity GlennEVP AND GC
|
Exercise / conversionCommon Stock | 14,093 | $1.62 | $22,830.66 |
DisclosureSEC source: 0001415889-17-000785 · form4-05172017_020549.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 21:03 UTC |
YANG MICHAEL J.EVP AND CCO
|
GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $35.86 | $0.00 |
DisclosureSEC source: 0001415889-17-000528 · form4-03312017_020314.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP AND CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2027-03-28 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on March 29, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:39 UTC |
YOUNG TODD S.EVP AND CFO
|
GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $36.54 | $0.00 |
DisclosureSEC source: 0001415889-17-000409 · form4-03102017_050314.xml · derivative · entry 1 YOUNG TODD S. · CIK 0001682584 · EVP AND CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2027-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:38 UTC | GrantStock Option (right to buy) · Derivative | 93,750 | $0.00 Strike: $36.54 | $0.00 |
DisclosureSEC source: 0001415889-17-000408 · form4-03102017_050352.xml · derivative · entry 1 Stankovic Srdjan R. · CIK 0001432545 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 93,750 shares Expires 2027-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
|
| March 08, 2017 Filed Mar 11, 2017 01:37 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
GrantStock Option (right to buy) · Derivative | 33,750 | $0.00 Strike: $36.54 | $0.00 |
DisclosureSEC source: 0001415889-17-000407 · form4-03102017_050310.xml · derivative · entry 1 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 33,750 shares Expires 2027-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:36 UTC |
DAVIS STEPHENDirector · PRESIDENT AND CEO
|
GrantStock Option (right to buy) · Derivative | 243,750 | $0.00 Strike: $36.54 | $0.00 |
DisclosureSEC source: 0001415889-17-000405 · form4-03102017_050352.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,750 Underlying: Common Stock · 243,750 shares Expires 2027-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:36 UTC |
Baity GlennEVP AND GC
|
GrantStock Option (right to buy) · Derivative | 46,875 | $0.00 Strike: $36.54 | $0.00 |
DisclosureSEC source: 0001415889-17-000406 · form4-03102017_050329.xml · derivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 46,875 shares Expires 2027-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:01 UTC |
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,856 | $0.00 Strike: $34.45 | $0.00 |
DisclosureSEC source: 0001415889-17-000308 · form4-02232017_030207.xml · derivative · entry 3 Moore Terrence O · CIK 0001454276 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 7,856 shares Expires 2025-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.